Company profile
DJS Antibodies Unlocking immunology to deliver revolutionary medicines
DJS Antibodies Ltd is a UK company with status active founded in 2014 based in South East England.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
TM01 | Transaction MzQzMzEyMDUzMGFkaXF6a2N4
Published 24 Aug 2024 07:37
AP01 | Transaction MzQzMzEyMDUzMWFkaXF6a2N4
Published 22 Aug 2024 15:18
Company registered at Companies House
1 Jun 2020 to 30 Nov 2020
no public description
1 Apr 2019 to 30 Jun 2021
"It is estimated that 15.1% of adults will develop advanced chronic kidney disease (CKD) during their lifetime. In the UK, NHS spends £1.23 billion treating CKD each year, with approximately £500 million being spent on dialysis for patients with end-stage renal failure. These patients need to visit hospital at least 3 times weekly for sessions of 4-6 hour...
1 Dec 2017 to 30 Nov 2019
"DJS Antibodies has a novel technology which allows us to discover antibody therapeutics against previously intractable disease targets. We are utilising this technology to develop a new drug to treat colorectal and pancreatic cancers. In particular, our antibody will act alongside recently developed therapies which activate patients' immune systems to fi...
1 Nov 2015 to 30 Jun 2016
We have devised a new strategy for the discovery of a class of medicines called monoclonal antibodies (mAbs). mAbs are medical ‘magic bullets’ that can specifically target diseases in our bodies, and have been very successful in the treatment of conditions such as inflammatory disease and cancer. Unfortunately, however, some of the most attractive disease...
